Johnson & Johnson
Global healthcare company offering pharma, devices.
Core HR Platforms Analyst
Hybrid work is required; the description also identifies Pune, Maharashtra, India, as the local recruiting location.
About the job
- A bachelor's degree in Information Systems, Computer Science, Business Administration, Human Resources, or a related field is required.
- Typically 2–4 years of relevant experience in human resources systems support, Workday HCM, business operations, analytics, or a related field is required.
- Strong attention to detail and the ability to work accurately with system data are required.
- Basic understanding of enterprise platforms, databases, or business systems is required.
- Proficiency in Microsoft Excel and standard reporting tools is required.
- Ability to follow defined processes and meet service-level expectations is required.
- English proficiency is required.
- Support the operation and administration of core enterprise platforms, ensuring system stability, data accuracy, and timely issue resolution.
- Perform routine system monitoring, data validation, and quality checks in line with defined controls and standards.
- Assist with user access, basic configuration, and troubleshooting activities across supported platforms.
- Prepare and maintain standard and ad hoc reports and dashboards to support business and human resources stakeholders.
- Support system enhancements, upgrades, and testing activities in partnership with information technology and functional teams.
- Document processes, standard operating procedures, and knowledge articles to support consistent service delivery.
- Identify opportunities for process improvement, automation, and improved user experience across core platforms.
- Print, stamp or seal, mail or ship, distribute, and route documents for wet signatures where local management is required.
- Store, archive, and retrieve human resources documents; fulfill requests; coordinate offsite storage; and scan and name documents for Veeva.
- Upload and submit filings; print and hand-deliver documents to agencies; support audits; and coordinate onsite audits.
- A master's degree is preferred.
- Exposure to human resources systems or core enterprise platforms, such as human resources information systems, learning systems, or workforce systems.
- Experience supporting global or shared-services environments.
- Familiarity with reporting, analytics, or data visualization tools.
- Experience working in a regulated or multinational organization.
- Systems, analytics, or human resources technology certifications are preferred but not required.
About the company
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 sales rose 6.6% to $25.3 billion, with raised full-year guidance.
- TREMFYA posted $2 billion quarterly sales in July 2026, growing 72.5%.
- CAPLYTA met its bipolar mania primary endpoint on September 21, 2026.
What critics are saying
- Talc litigation still threatens cash flow after the $5.5 billion settlement announced July 2026.
- Apollo's orthopedics talks signal DePuy Synthes weakness and forced portfolio shrinkage.
- AbbVie's etentamig and biosimilars pressure CARVYKTI, TREMFYA, and post-STELARA growth.
What makes Johnson & Johnson unique
- J&J has 28 billion-dollar products, reducing dependence on any single franchise.
- TREMFYA and DARZALEX offset STELARA erosion, proving resilient portfolio management.
- CAPLYTA, CARVYKTI, and RYBREVANT deepen leadership across psychiatry, cell therapy, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -2%2 year growth
↓ -1%Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.
Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.
Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.
Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.
Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.